FibroGen. has filed a patent for compounds and pharmaceutical compositions targeting histone lysine demethylase5 (KDM5), specifically KDM5B, for treating related conditions. Claim 1 specifies a compound of formula I. GlobalData’s report on FibroGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights FibroGen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on FibroGen, Human telomerase RT biomarker was a key innovation area identified from patents. FibroGen's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application US20240002344A1 discloses a series of compounds represented by formulas I, II, III, IV, and V, along with their various derivatives and analogs. These compounds are designed to inhibit the activity of histone lysine demethylase, a key enzyme involved in gene regulation. The compounds described in the patent claim are structurally defined by the substitution patterns on the core scaffold, with specific variations in the X and W groups, as well as R1, R2, R5, and other substituents. The patent also covers pharmaceutical compositions containing these compounds along with additional therapeutic agents, highlighting their potential application in the treatment of various diseases.

Furthermore, the patent application outlines a method for inhibiting the activity of histone lysine demethylase by using the disclosed compounds in a pharmaceutical composition. By bringing the histone lysine demethylase enzyme into contact with an inhibitory-effective amount of the pharmaceutical composition, the compounds described in the patent can effectively modulate the enzyme's activity. This method underscores the potential therapeutic utility of the compounds in regulating gene expression and treating conditions where histone lysine demethylase plays a crucial role. Overall, the patent application provides a detailed insight into the structural features, pharmaceutical compositions, and methods of using these compounds to target histone lysine demethylase, opening up new possibilities for drug development in the field of epigenetics.

To know more about GlobalData’s detailed insights on FibroGen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies